0000000000155200
AUTHOR
Wu J
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …
Search for Single Top Production in $e^{+} e^{-}$ Collisions at $\sqrt{s}$ up to 209 GeV
Single top production via the flavour changing neutral current reactions e+e- -> \bar{t}c, \bar{t}u is searched for within the 214 pb-1 of data collected by ALEPH at centre-of-mass energies between 204 and 209 GeV. No deviation from the Standard Model expectation is observed and upper limits on the single top production cross sections are derived. The combination with data collected at lower centre-of-mass energies yields an upper limit on the branching ratio BR(t -> Zc)+BR(t -> Zu) 14%, for BR(t -> ��c)+BR(t -> ��u)= 0 and mt=174 GeV/c2.